← FDA DRUG APPROVALS

FDA ANDA · ANDA091476

FLUVOXAMINE MALEATE

Sponsor: PH HEALTH

APPLICATION
ANDA091476
TYPE
ANDA
ORIGINAL APPROVAL
2013-03-13
LATEST ACTION
2023-12-11
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

FLUVOXAMINE MALEATEPrescription
FLUVOXAMINE MALEATE 150MG · CAPSULE, EXTENDED RELEASE · ORAL
FLUVOXAMINE MALEATEPrescription
FLUVOXAMINE MALEATE 100MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2023-12-11Labeling · Supplement 24 · standardAP
2023-08-18Labeling · Supplement 23 · standardAP
2023-08-10Labeling · Supplement 11 · standardAP
2015-09-16Labeling · Supplement 6 · standardAP
2013-03-13OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →